A B S T R A C T In livers of fetuses of 220-340 g body wt, total cytosolic tyrosine aminotransferase activity was 1.0 nmol of product/mg of protein per min, and the corresponding values for autopsy livers of newborns of 740-1,475 g and 2,600-3,650 g were 1.5 and 5.7, respectively, as compared with the adult value of 12.7. On the other hand, p-hydroxyphenylpyruvate dioxygenase activity is at adult level already in fetuses <340 g body wt. The Km value for tyrosine of tyrosine aminotransferase (1 mM) was considerably higher than the corresponding value for p-hydroxyphenylpyruvate of p-hydroxyphenylpyruvate dioxygenase (50 AM).
INTRODUCTION
Transient neonatal tyrosinemia is the most common disorder of amino acid metabolism encountered in human infants, occurring in as many as 30% of premature newborns (1) (2) (3) (4) (5) (6) . This condition is characterized by marked elevation of serum tyrosine concentration and urinary excretion of tyrosine, phydroxyphenylpyruvate, and p-hydroxyphenyllactate (4) . The abnormality is spontaneously corrected most often during the first weeks but sometimes persists up to 2 or 3 mo of age (1) (2) . The condition has been reported to be potentially harmful to the central nervous system (5) , and in one case, elevated concentrations of homovanillic and 5-hydroxyindoleacetic acids in the cerebrospinal fluid have been demonstrated (7).
The main catabolic pathway of tyrosine begins with transamination by hepatic cytosolic L-tyrosine:2-oxoglutarate aminotransferase (EC 2.6.1.5) yielding p-hydroxyphenylpyruvate. This enzyme is under strict hormonal control and is inducible by corticosteroids, glucagon, catecholamines, dibutyryl-cAMP, and by tyrosine in rat (8) and in fetal human liver in organ culture (9) . The following enzymes of the pathway, p-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27), homogentisate 1 ,2-dioxygenase (EC 1.13.11.5), maleylacetoacetate isomerase (EC 5.2.1.2), and fumarylacetoacetase (EC 3.7.1.2) are not known to be inducible by hormones. Tyrosine aminotransferase is the rate limiting enzyme of this pathway in hepatocytes prepared from adult rat liver (10) and in organ culture of fetal rat liver (11) .
The metabolic basis of transient neonatal tyrosinemia is unknown. Early studies suggested that vitamin C could correct this abnormality (1) (2) (3) (4) . It was believed that ascorbic acid is a cofactor of p-hydroxyphenylpyruvate dioxygenase (12) . As p-hydroxyphenylpyruvate is excreted into the urine, it was natural that it was assumed that transient neonatal tyrosinemia is due to incomplete maturation of the activity of p-hydroxyphenylpyruvate dioxygenase.
In the light of the findings of the present work and a literature survey we now challenge this concept and suggest that the transamination step is rate limiting in the catabolism of tyrosine in the premature infant. Therefore, it is probable that transient neonatal tyrosinemnia is caused by delayed induction of hepatic tyrosine aminotransferase.
METHODS
Liver samples were obtained from legal abortions and at routine autopsies performed on the 1st and 2nd d post mortem on newborn babies and adults. A part of each sample was homogenized in 4 vol of 5 mM mercaptoethanol, 1% vate were 50 and 30 ,uM, respectively. The values obtained for the fetal liver enzyme were, thus, slightly 10 higher than those for adult enzyme but we do not believe this difference to be significant. Triton X-100 and 50 mM sodium phosphate, pH 7.4, and the remaining part in 125 mM potassium phosphate, pH 7.6. The homogenates were centrifuged at 20,000 g for 20 min, and the supernatant of the former was assayed for p-hydroxyphenylpyruvate dioxygenase (13) and that of the latter for tyrosine aminotransferase (14, 15) . Protein was estimated by the method of Lowry et al. (16) . Km values were estimated by the Lineweaver-Burk method.
RESULTS
The activities of tyrosine aminotransferase and p-hydroxyphenylpyruvate dioxygenase in fetal or newborn and adult liver samples are shown in Fig. 1 (18) . There is evidence that p-hydroxyphenylpyruvate is actively secreted by the kidney (19) . It can therefore be understood that this metabolite is excreted despite insufficient hepatic tyrosine aminotransferase activity.
Several studies have suggested that administration of vitamin C normalizes serum tyrosine concentration in transient neonatal tyrosinemia (1) (2) (3) 6 ). However, this condition resolves spontaneously and abruptly, which can easily lead to the misinterpretation that the therapy had a curative effect. The only study in which the time course of the condition was followed showed no effect of vitamin C (20) in a very large patient material. Finally, ascorbic acid is not a cofactor of phydroxyphenylpyruvate dioxygenase (17) .
In conclusion, we propose that transient neonatal tyrosinemia is due to a defect in the regulation of hepatic tyrosine aminotransferase.
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